Synbio International has partnered with CRO Services Pty – a subsidiary of Resonance Health – to conduct a clinical trial for an innovative AI-based facial screening technology. The study aims to validate a non-invasive tool for identifying early markers of mental health disorders.
FacialDx Nims: Enhancing clinical assessment The technology, branded as FacialDx Nims, utilizes artificial intelligence to analyze a patient’s facial biological data. The upcoming Australian study will specifically evaluate its efficacy in detecting early signs of:
-
Post-traumatic stress disorder (PTSD).
-
Major depressive disorder (MDD).
Synbio’s leadership clarified that the tool is intended to empower healthcare professionals by supplementing, rather than replacing, traditional clinical assessments. By relying on objective biological indicators rather than solely on subjective interpretation, the system aims to provide a more reliable diagnostic aid for clinicians.
Strategic advantages of the Australian study The trial is scheduled to commence within the next few weeks. Conducting the research in Australia offers significant cost and timeline efficiencies while adhering to globally recognized ethical and clinical standards.
Data harvested from this study will be pivotal in shaping Synbio’s regulatory strategy, including future submission plans to the U.S. FDA. Furthermore, the strategic agreement includes a provision allowing Synbio to convert clinical trial expenditures into equity within FacialDx, the developer of the AI technology.
Source: https://www.bioxconomy.com/clinical-and-research/untitled